Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Template:SUIT-002"

From Bioblast
Line 24: Line 24:
| ([[F]])
| ([[F]])
| FAO
| FAO
| {{Template:SUIT F}} Β 
| 1D;2M.1;3Oct
Β 
{{Template:SUIT F}} Β 


|-
|-
Line 31: Line 33:
| [[F]]
| [[F]]
| FAO
| FAO
| {{Template:SUIT F}} {{Template:SUIT OXPHOS}} {{Template:SUIT c}}
| 1D;2M.1;3Oct;3c
Β 
{{Template:SUIT F}} {{Template:SUIT OXPHOS}} {{Template:SUIT c}}


|-
|-
Line 38: Line 42:
| [[F]]
| [[F]]
| FAO
| FAO
| {{Template:SUIT F}} {{Template:SUIT M_high}} {{Template:SUIT OXPHOS}} Β 
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot
Β 
{{Template:SUIT F}} {{Template:SUIT M_high}} {{Template:SUIT OXPHOS}} Β 


|-
|-
Line 44: Line 50:
| [[OctPM]]<sub>''P''</sub>
| [[OctPM]]<sub>''P''</sub>
| [[FN]]
| [[FN]]
| FAO&CI
| F<small>&</small>CI
| {{Template:SUIT N}} {{Template:SUIT OXPHOS}}
| 1D;2M.1;3Oct;4M2;5P
Β 
{{Template:SUIT N}} {{Template:SUIT OXPHOS}}


|-
|-
Line 51: Line 59:
| [[OctPGM]]<sub>''P''</sub>
| [[OctPGM]]<sub>''P''</sub>
| [[FN]]
| [[FN]]
| FAO&CI
| F<small>&</small>CI
| {{Template:SUIT N}} {{Template:SUIT OXPHOS}}
| 1D;2M.1;3Oct;4M2;5P;6G
Β 
{{Template:SUIT N}} {{Template:SUIT OXPHOS}}


|-
|-
Line 58: Line 68:
| [[OctPGMS]]<sub>''P''</sub>
| [[OctPGMS]]<sub>''P''</sub>
| [[FNS]]
| [[FNS]]
| FAO&CI&II
| F<small>&</small>CI<small>&</small>II
| {{Template:SUIT FNS}} {{Template:SUIT OXPHOS}}
| 1D;2M.1;3Oct;4M2;5P;6G;7S
Β 
{{Template:SUIT FNS}} {{Template:SUIT OXPHOS}}


|-
|-
Line 65: Line 77:
| [[OctPGMSGp]]<sub>''P''</sub>
| [[OctPGMSGp]]<sub>''P''</sub>
| [[FNSGp]]
| [[FNSGp]]
| FAO&CI&II&GpDH
| F<small>&</small>CI<small>&</small>II<small>&</small>GpDH
| {{Template:SUIT FNSGp}} {{Template:SUIT OXPHOS}}
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp
Β 
{{Template:SUIT FNSGp}} {{Template:SUIT OXPHOS}}


|-
|-
Line 72: Line 86:
| [[OctPGMSGp]]<sub>''E''</sub>
| [[OctPGMSGp]]<sub>''E''</sub>
| [[FNSGp]]
| [[FNSGp]]
| FAO&CI&II&GpDH
| F<small>&</small>CI<small>&</small>II<small>&</small>GpDH
| {{Template:SUIT FNSGp}} {{Template:SUIT U*}}
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U
Β 
{{Template:SUIT FNSGp}} {{Template:SUIT U*}}


|-
|-
Line 79: Line 95:
| [[SGp]]<sub>''E''</sub>
| [[SGp]]<sub>''E''</sub>
| [[SGp]]
| [[SGp]]
| CII&GpDH
| CII<small>&</small>GpDH
| {{Template:SUIT SGp}} {{Template:SUIT ET}}
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot
Β 
{{Template:SUIT SGp}} {{Template:SUIT ET}}


|-
|-

Revision as of 17:50, 11 January 2019

Steps and respiratory states

1D;2M.1;3Oct;3c;4M2;5P;6G;7S;8Gp;9U;10Rot-.png

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1D ROX ADP is added to stimulate consumption of endogenous fuel-substrates.

Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.

2M.1 Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
3Oct OctP (F) FAO 1D;2M.1;3Oct

Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.

3c OctMcP F FAO 1D;2M.1;3Oct;3c

Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state. Addition of cytochrome c yields a test for integrity of the mtOM (cytochrome c control efficiency). Stimulation by added cytochrome c would indicate an injury of the mtOM and limitation of respiration in the preceding state without added c due to loss of cytochrome c. Typically, cytochrome c is added immediately after the earliest ADP-activation step (OXPHOS capacity P with saturating [ADP]).

4M2 OctMP F FAO 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot

Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. High concentration of malate, typically 2 mM, saturates the N-pathway. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

5P OctPMP FN F&CI 1D;2M.1;3Oct;4M2;5P

NADH-linked substrates (type N-pathway to Q). OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

6G OctPGMP FN F&CI 1D;2M.1;3Oct;4M2;5P;6G

NADH-linked substrates (type N-pathway to Q). OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

7S OctPGMSP FNS F&CI&II 1D;2M.1;3Oct;4M2;5P;6G;7S

Respiratory stimulation by simultaneous action of the F-pathway, N-pathway, and S-pathway, with convergent electron flow in the FNS-pathway for reconstitution of TCA cycle function and additive or inhibitory effect of F. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

8Gp OctPGMSGpP FNSGp F&CI&II&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp

Respiratory stimulation by simultaneous action of fatty acid (F), type N substrates (N), succinate (S), and glycerophosphate with convergent electron flow in the FNSGp-pathway to the Q-junction. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

9U OctPGMSGpE FNSGp F&CI&II&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U

Respiratory stimulation by simultaneous action of fatty acid (F), type N substrates (N), succinate (S), and glycerophosphate with convergent electron flow in the FNSGp-pathway to the Q-junction. Uncoupler titration (avoiding inhibition by high uncoupler concentrations) to obtain electron transfer (ET) capacity E (noncoupled ET-state). Test for limitation of OXPHOS capacity P by the phosphorylation system (ANT, ATP synthase, phosphate transporter) relative to ET capacity E in mt-preparations: E-P control efficiency and E-L coupling efficiency. In living cells: E-R control efficiency and E-L coupling efficiency.

10Rot SGpE SGp CII&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot

Respiratory stimulation by action of succinate and glycerophosphate, Gp, with convergent electron flow in the SGp-pathway (CII&GpDH-linked pathway to the Q-junction). Noncoupled electron transfer state, ET state, with ET capacity E.

11Ama ROX Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).
Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB